Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 08, 2022 16:17 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics Reports Second-Quarter 2022 Financial Results, Provides Operational Updates

Positive feedback from pre-new drug application (NDA) meeting with U.S. Food and Drug Administration (FDA) focused on TRIDENT-1 registrational study of repotrectinibInitiated the Phase 1b/2 SHIELD-2...
July 27, 2022 16:05 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics Provides Regulatory Update for Repotrectinib for the Treatment of ROS1+ Advanced NSCLC

SAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer...
June 24, 2022 09:00 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics and MD Anderson Announce Strategic Alliance to Advance Precision Cancer Therapies

HOUSTON and SAN DIEGO, June 24, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted...
May 26, 2022 16:30 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics to Participate in Upcoming Investor Conferences

SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer...
May 16, 2022 08:30 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics Announces Appointment of Steve Sabus as Chief Commercial Officer

SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer...
May 10, 2022 16:05 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics Reports First-Quarter 2022 Financial Results, Provides Operational Updates

Granted Third Breakthrough Therapy Designation (BTD) for Repotrectinib for the treatment of patients with ROS1-positive Metastatic NSCLC who have been Previously Treated with One ROS1 TKI and who have...
May 10, 2022 08:30 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients With One Prior ROS1 Tyrosine Kinase Inhibitor and no Prior Chemotherapy

SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer...
May 05, 2022 09:00 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics Announces Pipeline Expansion, Licensing of TPX-4589 (LM-302), A Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate for Gastrointestinal Cancers, From Lanova Medicines

Strategic Expansion of Turning Point Precision Oncology Portfolio TPX-4589 (LM-302) Currently in Two Ongoing Phase 1 Studies Agreement Includes Potential Broader Scope to Collaborate on up to Three...
April 28, 2022 07:30 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics and Zai Lab Announce Topline Analysis in China Subpopulation for Repotrectinib in ROS1-Positive NSCLC Cohorts Within Global Phase 1/2 TRIDENT-1 Study

91% confirmed objective response rate (cORR) (10/11) in China subpopulation by Blinded Independent Central Review (BICR) in TKI-naïve cohort (EXP-1) In the TKI-naïve China subpopulation by BICR, the...
April 12, 2022 16:46 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics Announces Positive Topline Data by Blinded Independent Central Review for Repotrectinib Across All ROS1-Positive NSCLC Cohorts of Phase 1/2 TRIDENT-1 Study

In a total of 71 TKI-naïve patients, confirmed objective response rate (cORR) of 79% (95% CI: 68, 88)In the TKI-naïve population with approximately 10 months of follow-up, initial estimated durability...